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Abstract
Background: According to the 2018 NIA-AA research framework, Alzheimer’s disease (AD) is not defined by the
clinical consequences of the disease, but by its underlying pathology, measured by biomarkers. Evidence of both
amyloid-β (Aβ) and phosphorylated tau protein (p-tau) deposition—assessed interchangeably with amyloid-
positron emission tomography (PET) and/or cerebrospinal fluid (CSF) analysis—is needed to diagnose AD in a living
person. Our aim was to test the new NIA-AA research framework in a large cohort of cognitively impaired patients
to evaluate correspondence between the clinical syndromes and the underlying pathologic process testified by
biomarkers.
Methods: We retrospectively analysed 628 subjects referred to our centre in suspicion of dementia, who
underwent CSF analysis, together with neuropsychological assessment and neuroimaging, and were diagnosed
with different neurodegenerative dementias according to current criteria, or as cognitively unimpaired. Subjects
were classified considering CSF biomarkers, and the prevalence of normal, AD-continuum and non-AD profiles in
each clinical syndrome was calculated. The positivity threshold of each CSF biomarker was first assessed by receiver
operating characteristic analysis, using Aβ-positive/negative status as determined by amyloid-PET visual reads. The
agreement between CSF and amyloid-PET data was also evaluated.
Results: Among patients with a clinical diagnosis of AD, 94.1% were in the AD-continuum, whereas 5.5% were
classified as non-AD and 0.4% were normal. The AD-continuum profile was found also in 26.2% of frontotemporal
dementia, 48.6% of Lewy body dementia, 25% of atypical parkinsonism and 44.7% of vascular dementia. Biomarkers’
profile did not differ in amnestic and not amnestic mild cognitive impairment. CSF Aβ levels and amyloid-PET tracer
binding negatively correlated, and the concordance between the two Aβ biomarkers was 89%.
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Conclusions: The examination of the 2018 NIA-AA research framework in our clinical setting revealed a good, but
incomplete, correspondence between the clinical syndromes and the underlying pathologic process measured by
CSF biomarkers. The AD-continuum profile resulted to be a sensitive, but non-specific biomarker with regard to the
clinical AD diagnosis. CSF and PET Aβ biomarkers were found to be not perfectly interchangeable to quantify the
Aβ burden, possibly because they measure different aspects of AD pathology.
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Introduction
The diagnosis of probable Alzheimer’s disease (AD) re-
quires core clinical criteria [1]. Cerebrospinal fluid (CSF)
and neuroimaging biomarkers enhance the specificity of
the criteria in clinical and research settings [1]. In 2018,
the National Institute of Age-Alzheimer’s Association
shifted the definition of AD to a biological construct [2].
According to the new research framework (2018-NIA-
AA-RF), AD is not defined by its clinical consequences,
but by its underlying pathology as measured during life-
time by biomarkers [2]. The amyloid/tau/neurodegener-
ation (AT(N)) classification is used to divide biomarkers
into those measuring β-amyloid (Aβ) deposition (A)
[CSF Aβ levels or Aβ-positron emission tomography
(PET)], pathologic phosphorylated tau (T) [CSF
phospho-tau (p-tau) levels or tau-PET], and neurodegen-
eration (N) [18F-fluorodeoxyglucose-PET (FDG-PET),
magnetic resonance imaging (MRI), or CSF total tau (t-
tau) levels] [3]. Regardless of the presence of clinical
symptoms, both Aβ and p-tau pathology are required for
classification as AD, whereas Aβ deposition alone is an
early sign, labelled AD pathologic change [2]. CSF and
PET biomarkers are considered interchangeable in dem-
onstrating AD pathology, assuming that they provide the
same information [2]. Nevertheless, while Aβ-PET
tracers bind to Aβ fibrils and give both quantitative and
qualitative data about the topology of Aβ deposition,
CSF biomarkers do not provide any topological infor-
mation. Moreover, Aβ-PET can be easily interpreted
as positive or negative by visual inspection, whereas
general cut-offs for CSF biomarkers are lacking and
the existing ones show high variability among centres
[4–6]. Standardisation of measurements and protocols
are ongoing [7].
The 2018-NIA-AA-RF retains also a staging for clin-
ical severity, ranging from cognitively unimpaired (CU)
to mild cognitive impairment (MCI) and dementia [2].
However, the criteria are currently supposed to be used
in research setting only, and their validity needs to be
examined before adopted into clinical practice [2].
The aim of this work was to test the 2018-NIA-AA-RF
in the clinical scenario of a large cohort of cognitively
impaired patients to evaluate possible correspondence
between the clinical syndromes and the underlying
pathologic process testified by biomarkers. Due to the
availability of our centre, we used only CSF data to clas-
sify subjects accordingly to the 2018-NIA-AA-RF. CSF
biomarker positivity thresholds for subject dichotomiza-
tion were first assessed in a subgroup of subjects who
underwent both CSF analysis and 18F-florbetapir-PET
(amyloid-PET).
Methods
Design of the study
We tested the 2018-NIA-AA-RF by retrospectively ana-
lysing all subjects who underwent lumbar puncture (LP)
for diagnostic purpose in the AD Unit of the Ospedale
Maggiore Policlinico, University of Milan, Italy, from
June 2011 to December 2017. Participants were referred
to our centre in suspicion of dementia, and they all re-
ceived—in addition to LP—a complete neurological
examination, neuropsychological assessment and neuro-
imaging (brain MRI and/or FDG-PET). All the exams
were performed within a 365-day interval from subjects’
first visit. After the diagnostic work-up, subjects were di-
agnosed by expert neurologists with MCI, or dementia,
according to the specific criteria of each syndrome [1,
8–17]. A few individuals were instead CU. Regarding
AD, from 2011 to 2014, clinical diagnoses were sup-
ported by CSF (Aβ1-42, p-tau and t-tau) and/or neuroim-
aging (brain MRI and/or FDG-PET) biomarkers,
according to previous criteria [1, 9]. After the publica-
tion of the IWG-2 criteria in 2014 [10], CSF analysis or
amyloid PET were used to support the diagnosis of
probable AD in our clinical setting. Conversely, in line
with their current criteria [11–17], all the other demen-
tia syndromes were diagnosed combining clinical, neuro-
psychological and neuroimaging profiles, and CSF
biomarkers were used for excluding AD.
According to 2018-NIA-AA-RF, CSF biomarkers were
used to classify subjects into three binary categories: A+/
−, T+/− and N+/−, respectively. Participants had three
possible biomarker profiles and eight combinations: (1)
normal [A−T− (N−)]; (2) AD-continuum ([A+T−(N−)],
[A+T+(N−)], [A+T+(N+)] and [A+T−(N+)]); and (3)
non-AD pathologic change (non-AD) ([A−T+(N−)], [A
−T−(N+)] and [A−T+(N+)]) [2]. The positivity thresh-
olds for subject dichotomization were first assessed in a
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subgroup of our cohort who underwent both LP and
amyloid-PET within a 365-day interval in our unit for
research purpose. In line with previous literature [4, 5,
10, 18, 19], we used Aβ-positive/negative status—as de-
termined by amyloid-PET visual reads—to define our
CSF positivity thresholds. We considered amyloid-PET
the most suitable surrogate in vivo marker for determin-
ing the amyloid burden due to its high correlation with
neuropathological results [4, 20–23].
CSF analysis
CSF samples were collected by LP in the L3/L4 or L4/L5
interspace and centrifuged in 8000 rpm for 10min. The
supernatants were aliquoted in polypropylene tubes and
stored at − 80 °C until use. CSF Aβ1-42, p-tau and t-tau
were measured by using the commercially available
sandwich enzyme-linked immunosorbent assay kits
(Fujirebio, Ghent, Belgium). We also calculated the ra-
tios of t-tau/Aβ1-42 and p-tau/Aβ1-42.
Amyloid-PET imaging
Amyloid-PET scans were obtained with a Biograph
Truepoint 64 PET/CT scanner (Siemens, Erlangen,
Germany). All patients underwent PET scanning at rest
after intravenous injection of 370MBq. Amyloid-PET
data were first qualitatively analysed by a trained physi-
ologist using a binary method of interpretation for relat-
ing “positive” or “negative” scans to neuropathologically
defined categories of Aβ plaque density. Structural MRI
was also acquired, and FLAIR-weighted images and PET
images were co-registered to individual volumetric T1-
weighted images. After PET/MRI co-registration,
ImcCalc of Statistical Parametric Mapping (SPM12,
Wellcome Department of Cognitive Neurology, London,
UK) was used to derive standardised uptake value (SUV)
PET maps as SUV = AC/(radiotracer dose/BW). AC rep-
resents activity concentration in a given voxel [kBq/ml],
radiotracer dose is the injected tracer dose corrected for
residual activity in the syringe [MBq] and BW is the
body weight [kg]. SUV maps were calculated in the grey
matter (GM) of anterior cingulate gyrus, frontal lobe,
parietal lobe, posterior cingulate gyrus, precuneus, tem-
poral lobe, and of the average of these six regions (GM
mean). The whole cerebellum was the reference region
for the SUV relative ratio (SUVR). For the GM mean, we
applied the validated threshold for amyloid-PET SUVR
(1.11) [24, 25].
Statistical analysis
All statistical analyses were conducted with Microsoft-
Excel 2011, SPSS 21.0 (SPSS Inc., Chicago, IL, USA), or
Graph-Pad-PRISM 6.0 (GraphPad Software, La Jolla,
CA). Comparisons between amyloid-PET-positive (aP+)
and amyloid-PET-negative (aP−) subjects were
performed using non-parametric unpaired t tests
(Mann-Whitney U test), except sex difference between
aP+ and aP− that was tested by Χ2 test. Using receiver
operating characteristic (ROC) analysis, we calculated
the area under the curve (AUC) of the CSF analyte and
ratio that best distinguished aP+ from aP− subjects. For
each parameter, sensitivity was defined as the positivity
rate in aP+ subjects, and specificity as the negativity rate
in aP− subjects. The value of each CSF analyte or ratio
with the highest Youden index (sensitivity + specificity −
1) was selected as the cut-off. The prevalence of normal,
AD-continuum and non-AD in each clinical syndrome
and in aP+ and aP− subjects was calculated and com-
pared by Χ2 test. Correlations between amyloid-PET
SUVR and CSF biomarkers were performed using Spear-
man coefficient, assuming a non-normal distribution of
data. The concordance between amyloid-PET profile
and CSF profile was defined as the sum of aP+ with
pathologic CSF analyte or ratio levels and aP− with nor-
mal CSF analyte or ratio levels, divided by the entire co-
hort size. For all the analyses, we set the statistical
threshold at p < 0.05.
Determination of positivity thresholds for CSF biomarkers
Forty-four subjects underwent amyloid-PET and LP
within a 365-day period for research purpose and were
considered to identify positivity thresholds for CSF bio-
markers. Amyloid-PET was visually assessed as positive
in 37 patients (aP+) and negative in 7 (aP−). Accord-
ingly, GM mean SUVR was > 1.11 and ≤ 1.11 in all aP+
and aP− participants, respectively. The AUC for the de-
tection of amyloid-PET positivity was 0.86 (95% CI
0.71–1.00, p = 0.002) for Aβ1-42 and 0.80 (95% CI 0.58–
1.03, p = 0.01) for p-tau/Aβ1-42. The following cut-offs
that maximised the Youden index for predicting
amyloid-PET positivity were selected: Aβ1-42 < 660 pg/ml
(sensitivity 0.89, specificity 0.71) and p-tau/Aβ1-42 > 0.09
(sensitivity 0.81, specificity 0.71, Additional file 1). In
line with the 2018-NIA-AA-RF [2], Aβ1-42 (cut-off < 660
pg/ml) resulted a better biomarker of β-amyloidosis
(A)—as compared with p-tau/Aβ1-42, due to the higher
accuracy, sensitivity and specificity in detection of
amyloid-PET positivity. Conversely, ROC analyses
showed that t-tau and p-tau (and t-tau/Aβ1-42) had an
insufficient accuracy in distinguishing aP+ from aP−
subjects (AUC 0.52, 0.61, 0.68, respectively; data not sig-
nificant). Thus, we decided to not calculate cut-offs for
these biomarkers, but to use standardly used cut-offs
[26] due to the (1) lack of tau-PET, FDG-PET and/or
quantitative MRI data and (2) inaccuracy we found in
the detection of amyloid-PET positivity of these bio-
markers. In conclusion, the following thresholds were
applied for patient dichotomization: Aβ1-42 < 660 pg/ml
(A), p-tau > 61 pg/ml (T) and t-tau > 500 pg/ml (N). The
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main characteristics of aP+ and aP− subjects are sum-
marised in Table 1.
Results
Application of the 2018-NIA-AA-RF into clinical practice
CSF data from 628 subjects were retrospectively ana-
lysed (Table 2). Among the 229 patients with a clinical
diagnosis of AD [1, 8–10], 162 had AD typical core cri-
teria, 36 logopenic primary progressive aphasia (PPA)
[11], 23 posterior cortical atrophy (PCA) [27] and 8
frontal variant AD (fv-AD) [10]. Among the 107 subjects
diagnosed as frontotemporal dementia (FTD), 82 had be-
havioural variant (bv)-FTD [12], 11 non-fluent PPA [11]
and 14 semantic PPA [11]. We included also 37 Lewy
body dementia (LBD) [13], 12 atypical parkinsonism
[progressive supranuclear palsy (PSP) [16] or corticoba-
sal syndrome (CBS) [14]], 5 idiopathic Parkinson’s dis-
eases [15], 67 vascular/mixed dementia (VaD/mixed)
[17] and 30 other dementia (see Table 2 for details).
MCI (n = 132) were divided in amnestic (n = 99; aMCI)
and not amnestic (n = 33; naMCI) [28, 29]. Nine individ-
uals were diagnosed as CU and remained CU after at
least 24-month follow-up.
According to their CSF data, participants were divided
in normal (n = 132), AD-continuum (n = 389) and non-
AD (n = 107) [2, 3]. The demographic data and a de-
tailed list of biomarker profiles are given in Table 2.
Correspondence between biological biomarkers and
clinical syndromes
The percentages of the three main biomarker profiles
(normal, AD-continuum and non-AD) in each clinical
syndrome are summarised in Fig. 1a, whereas Fig. 1b
and Table 2 provide a detailed representation of the per-
centages of all the eight biomarker profiles in the differ-
ent clinical syndromes considered. Among patients
diagnosed with AD, 94.1% were in the AD-continuum
according to 2018-NIA-AA-RF [2], whereas 5.5% were
classified as non-AD and 0.4% were normal. Particularly,
the AD profile was the most common in AD-diagnosed
patients (A+T+(N−) = 14.9% and A+T+(N+) = 51.6%),
followed by the AD pathologic change profile (A+T−(N
−) = 24.5%). Only 3.1% displayed an AD and non-AD
pathologic change profile. As concern AD-diagnosed pa-
tients with a non-AD profile, 2.1% was A−T+(N−), 0.4%
A−T−(N+) and 3% A−T+(N+) (Fig. 2). The AD-
continuum profile was significantly higher in patients
with clinically diagnosed AD as compared with all the
other diagnostic groups (Χ2 = 175.1; df = 4; p < 0.0001).
When considering all the eight biomarker subgroups,
the same trend was shown, although the significance
threshold was not reached (p > 0.05).
Similar percentages were found when considering only
typical AD [AD-continuum = 95%; non-AD = 5%] and
logopenic PPA [AD-continuum = 92%; non-AD = 5.5%;
Table 1 Characteristics of subjects who underwent 18F-florbetapir-positron emission tomography (amyloid-PET) and lumbar
puncture (LP) within a 365-day interval
Amyloid-PET positive* Amyloid-PET negative° p value
n 37 7
Age 71.4 ± 7.5 72.9 ± 3.6 0.76
M:F 13:24 3:4 0.69
Interval LP/amyloid-PET (days) 168.6 ± 119.5 246.4 ± 115.1 0.35
Aβ1-42 (pg/ml) 542.2 ± 119.2 842.3 ± 341.9 0.001
t-tau (pg/ml) 700.5 ± 493.3 681.3 ± 593.1 0.83
p-tau (pg/ml) 83.9 ± 38.5 67 ± 31.8 0.34
t-tau/Aβ1-42 1.30 ± 0.9 0.90 ± 1.0 0.13
p-tau/Aβ1-42 0.15 ± 0.07 0.09 ± 0.06 0.01
Amyloid-PET SUVR GM mean 1.47 ± 0.21 0.98 ± 0.10 < 0.0001
Amyloid-PET SUVR Ant Cing 1.49 ± 025 0.99 ± 0.16 < 0.0001
Amyloid-PET SUVR frontal 1.36 ± 0.25 0.89 ± 0.19 < 0.0001
Amyloid-PET SUVR parietal 1.28 ± 0.19 1.04 ± 0.15 0.005
Amyloid-PET SUVR post Cing 1.55 ± 0.22 0.97 ± 0.20 < 0.0001
Amyloid-PET SUVR precuneus 1.61 ± 0.27 1.02 ± 0.22 < 0.0001
Amyloid-PET SUVR temporal 1.50 ± 0.19 1.04 ± 0.15 < 0.0001
Data are expressed as mean ± SD, unless otherwise specified. p values by unpaired t test. *Among amyloid-PET-positive patients, 14 were diagnosed of
Alzheimer’s disease, 2 cerebral amyloid angiopathy, 20 mild cognitive impairment (MCI) and 1 mixed dementia. °Four amyloid-PET-negative patients had a
diagnosis of MCI, 1 frontotemporal dementia, 1 mixed dementia and 1 dysthymic dementia
All significant data (p value < 0.05) are presented in italic
Abbreviations: M males, F females, Aβ1-42 amyloid-β1-42, t-tau total tau, p-tau phosphorylated tau, SUVR standardised uptake value relative ratio, GM grey matter
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normal = 2.5%]. PCA resulted AD-continuum and non-
AD in 87% and 13% of cases, respectively. All fv-AD
were AD-continuum.
37.3% of FTD-diagnosed patients were non-AD (A
−T+(N−): 14%, A−T−(N+): 3.7%, A−T+(N+): 19.6%),
and 36.5% were normal (36.5%). Nevertheless, 26.2% of
FTD had an AD-continuum profile (A+T−(N−) = 10.4%,
A+T+(N−) = 6.5%, A+T+(N+) = 8.4%, A+T−(N+) =
0.9%).
Among LBD patients, 48.6% was AD-continuum (A+T
−(N−) = 24.3%, A+T+(N−) = 10.8%, A+T+(N+) = 8.1%,
A+T−(N+) = 5.4%), 35.1% normal and 16.2% non-AD (A
−T+(N−) = 5.4% A−T−(N+) = 2.7%, A−T+(N+) = 8.1%);
75% of CBS/PSP patients was normal, and 25% AD-
continuum (A+T−(N−) = 8.3%, A+T+(N+) = 16.7%). Be-
tween VaD/mixed patients, 44.7% was AD-continuum
(A+T−(N−) = 23.9%, A+T+(N−) = 8.9%, A+T+(N+) =
11.9%), 29.8% non-AD (A−T+(N−) = 14.9%, A
−T+(N+) = 14.9%) and 25.4% normal. Seven out of the 9
CU had a normal profile (77.8%), but 2 CU subjects had
AD pathologic change profile (A+T−(N− 22.2%)) [2],
without clinical symptoms after 48-month follow-up.
MCI-diagnosed patients displayed more often an AD-
continuum profile (62%; A+T−(N−) = 26.5%, A+T+(N
−) = 13.6%, A+T+(N+) = 18.9%, A+T−(N+) = 3%), but
20.4% was normal, and 17.5% non-AD (A−T+(N−) =
8.3%, A−T+(N+) = 9.2%). When dividing MCI patients in
aMCI and naMCI (Fig. 3), the AD-continuum was more
common in aMCI (67% versus 49%; X2 not significant;
p > 0.05). According to 2018-NIA-AA-RF [2], 37% of
aMCI and 18% of naMCI were classified as AD with
MCI (A+T+(N−)/A+T+(N+)), whereas 25% of aMCI and
30% of naMCI displayed the AD pathologic change pro-
file (A+T−(N−)). The prevalence of non-AD was 15% in
aMCI and 24% in naMCI, whereas 18% of aMCI and
27% of naMCI had the normal profile (Fig. 3).
Correlations between amyloid biomarkers
CSF Aβ1-42 levels and p-tau/Aβ1-42 ratio were signifi-
cantly different in aP+ and aP− groups (Table 1). CSF
Aβ1-42 levels—but not p-tau/Aβ1-42 ratio—negatively
correlated with amyloid-PET SUVR in GM mean (r = −
0.31, p = 0.039) and precuneus (r = − 0.30, p = 0.04). No
correlation between CSF and PET data and no signifi-
cant differences in aP+ and aP− patients were found for
t-tau, p-tau and t-tau/Aβ1-42 (p > 0.05).
When CSF biomarkers were dichotomized according
to the previously determined cut-offs, Aβ1-42 displayed
the higher concordance between amyloid-PET and CSF
data (89%), compared to p-tau/Aβ1-42 ratio (73%).
Among aP+ patients, 89% (n = 33/37) was classified as
AD-continuum by their CSF Aβ1-42 levels, 8% (n = 3/37)
as non-AD and 3% (n = 1/37) as normal. Conversely,
43% (n = 3/7) and 28.5% (n = 2/7) of aP− participants
had non-AD and normal CSF profiles, respectively, but
28.5% (n = 2/27) was AD-continuum (Additional file 2).
Correlation between Aβ1-42 and p-tau/Aβ1-42
According to our previously determined cut-off, 382 out
of 628 subjects had a pathologic p-tau/Aβ1-42 ratio (>
0.09), as compared with the 389 participants with patho-
logic CSF Aβ1-42 levels. When considering p-tau/Aβ1-42
Table 2 Demographic data and AT(N) cerebrospinal fluid biomarker profiles of all included patients, divided according to their
clinical syndrome
Normal^
(n = 132)
AD-continuum^
(n = 389)
Non-AD^
(n = 107)
n Age* M:F A−T−(N−) A+T−(N−) AD
pathologic change
A+T+(N−) AD A+T+(N+) AD A+T−(N+)
AD and non-AD
pathologic change
A−T+
(N−)
A−T
−(N+)
A−T+(N+)
AD 229 72 ± 8 96:133 1 (0.4) 56 (24.5) 34 (14.9) 118 (51.6) 7 (3.1) 5 (2.1) 1 (0.4) 7 (3.0)
FTD 107 73 ± 7 61:46 39 (36.5) 11 (10.4) 7 (6.5) 9 (8.4) 1 (0.9) 15 (14.0) 4 (3.7) 21 (19.6)
LBD 37 76 ± 5 20:17 13 (35.1) 9 (24.3) 4 (10.8) 3 (8.1) 2 (5.4) 2 (5.4) 1 (2.7) 3 (8.1)
PSP/CBS 12 69 ± 7 6:6 9 (75.0) 1 (8.3) – 2 (16.7) – – – –
PD 5 62 ± 18 2:3 4 (80.0) 1 (20%) – – – – – –
VaD/mixed 67 76 ± 6 37:30 17 (25.4) 16 (23.9) 6 (8.9) 8 (11.9) – 10 (14.9) – 10 (14.9)
Others° 30 – – 15 (50.0) 7 (23.3) 1 (3.3) 2 (6.7) – 1 (3.3) 1 (3.3) 3 (10.0)
MCI 132 73 ± 7 62:70 27 (20.4) 35 (26.5) 18 (13.6) 25 (18.9) 4 (3.0) 11 (8.3) – 12 (9.2)
CU 9 69 ± 6 8:1 7 (77.8) 2 (22.2) – – – – – –
Total 628 132 (21.0) 138 (22.0) 70 (11.1) 167 (26.6) 14 (2.2) 44 (7.0) 7 (1.1) 56 (9.0)
*Data are expressed as mean ± standard deviation. ^Data are expressed as number/total (percentage). °Among the 30 patients classified as “others” dementia, 4
had a diagnosis of sporadic cerebral amyloid angiopathy, 12 dysthymic dementia, 3 prion diseases, 1 Huntington disease, 1 Nasu-Hakola disease, 7 normal
pressure hydrocephalus and 2 metabolic dementia
Abbreviations: AD Alzheimer’s disease, M males, F females, FTD frontotemporal dementia, LBD Lewy body dementia, PSP progressive supranuclear palsy, CBS
corticobasal syndrome, PD idiopathic Parkinson’s disease, VaD vascular dementia, MCI mild cognitive impairment, CU cognitively unimpaired
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ratio—instead of Aβ1-42 levels—to classify patients ac-
cording to the 2018-NIA-AA-RF [2], 90.4% of clinically
diagnosed AD patients resulted AD-continuum (n = 207/
229), 7.9% normal (n = 18/229) and 1.7% non-AD (n = 4/
229). As concerns the other forms of dementia, when
using p-tau/Aβ1-42 ratio, the percentage of AD-
continuum was 40.1% in FTD patients (n = 43/107),
37.8% in LBD (n = 14/37), 16.7% in CBS/PSP (n = 2/12),
0% in PD (n = 0/5), 43.3% in VaD/mixed (n = 29/67),
61.4% in MCI (n = 81/132) and 0% in CU (n = 0/9;
Additional file 3).
Discussion
The 2018-NIA-AA-RF promotes a biological definition
of AD based on its underlying pathologic process as
measured by biomarkers. Evidence of both Aβ and
pathologic p-tau deposition—assessed interchangeably
with PET and/or CSF analysis—is needed to define AD
in a living person [2, 4].
We first used amyloid-PET to calculate the CSF bio-
marker positivity thresholds for patient dichotomization
as required by the AT(N) classification [3]. ROC ana-
lyses revealed that the optimal Aβ1-42 cut-off to predict
PET positivity was < 660 pg/ml (sensitivity 89%, specifi-
city 71%). This is in line with Palmqvist and colleagues
who described an optimal cut-off for CSF Aβ1-42 of <
647 pg/ml (sensitivity 95%, specificity 90%) [18]. Aβ1-42
presented the best AUC, the major concordance with
PET data, and was the only biomarker that correlated
with PET SUVR. As already described, we found that the
accuracy of CSF Aβ1-42 to predict cortical Aβ deposition
status did not increase if the ratio p-tau/Aβ1-42 was used
[5, 18, 30]. Given all these reasons, low CSF Aβ1-42 levels
resulted the best biomarker of β-amyloidosis. Con-
versely, p-tau, t-tau and t-tau/Aβ1-42 showed a bad diag-
nostic value in our ROC analyses, which is in
Fig. 1 a Percentages of the three AT(N) biomarker profiles (AD-continuum, non-AD and normal) in each clinical syndrome. b Percentages of all
the eight AT(N) biomarker profiles in each clinical syndrome. Percentages < 1% are not shown. AD Alzheimer’s disease (n = 229), FTD
frontotemporal dementia (n = 107), LBD Lewy body dementia (37), PSP progressive supranuclear palsy (n = 3), CBS corticobasal syndrome (n = 9),
VaD/mixed vascular/mixed dementia (n = 67), MCI mild cognitive impairment (n = 132), CU cognitively unimpaired (n = 9)
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Fig. 2 Number of Alzheimer’s disease-diagnosed patients (n tot = 229) for all the eight AT(N) biomarker profiles
Fig. 3 Percentages of all the eight AT(N) biomarker profiles in amnestic (n = 99) and not amnestic (n = 33) mild cognitive impairment (MCI)
(n tot = 132)
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accordance with some previous studies [18, 31, 32], but
not with others [19, 33]. A possible explanation for such
discrepancies may derive from differences in staging or
severity between cohorts studied.
When we applied the 2018-NIA-AA-RF to our cohort
of patients, we found a good—but incomplete—corres-
pondence between the diagnoses of AD made according
to the clinical follow-up and those made with CSF bio-
marker profiles. Among all AD patients, 94.1% displayed
an AD-continuum profile, but 5.5% were classified as
non-AD, and 0.4% as normal. Similar percentages were
found when considering both typical AD and logopenic
PPA. PCA had AD-continuum and non-AD CSF profiles
in 87% and 13% respectively, in line with the knowledge
that multiple pathologies can underlie PCA [27]. One
reason for this partial correspondence could be that
from 2011 to 2014, AD clinical diagnoses in our centre
were supported by both CSF and neuroimaging bio-
markers, according to previous criteria [1, 9]. Thus,
some patients with neuroimaging findings highly sug-
gestive of AD (i.e. decreased FDG-PET in temporo-
parietal cortex and/or atrophy on MRI in medial, basal
and lateral temporal lobe, and medial parietal cortex)
have been diagnosed with probable AD, even with a nor-
mal CSF profile. After the publication of the IWG-2 cri-
teria in 2014 [10], CSF analysis or amyloid PET were
used to support the diagnosis of probable AD in our
clinical setting.
Our analysis revealed a low specificity of the AD-
continuum profile, since it was found in a significant
number of other forms of dementia, such as 25% of
CBS/PSP, 44.7% of VaD/mixed, 48.6% of LBD and 26.2%
of FTD. Among the AD-continuum, the most common
CSF biomarker profile in all these syndromes was the
AD pathologic change (A+T−(N−)). The lack in specifi-
city of CSF Aβ1-42 levels is in accordance with previous
findings [34], suggesting that brain β-amyloidosis may
be a common comorbidity in other neurodegenerative
syndromes [34]. Aware that only neuropathological stud-
ies could help in understanding these findings, our ana-
lysis suggests that the AT(N)) classification has a limited
utility for differential diagnosis in the clinic setting. Not-
ably, as compared to CSF Aβ1-42 levels, p-tau/Aβ1-42 ra-
tio revealed a lower sensitivity with regard to the clinical
AD diagnosis, but a slight higher specificity in differenti-
ating the other forms of dementia, except FTD. This is
in line with previous studies, showing that p-tau/Aβ1-42
ratio has a higher accuracy in AD differential diagnosis,
as compared to Aβ1-42 levels [6, 35]. However, differently
from what was reported by De Souza et al., p-tau/Aβ1-42
ratio did not appear a useful tool to distinguish AD from
FTD [36].
As regards MCI, aMCI represents an early stage of
AD, especially when associated with low CSF Aβ levels
[37]. In our analysis, even though the AD-continuum
profile was more common in aMCI compared to naMCI,
data did not reach statistical significance and CSF pro-
files did not allow a substantial distinction between the
two subgroups. Notably, AD pathologic change (A+/T
−(N−))—that reflects Aβ deposition alone, thus repre-
senting an early sign of brain amyloidosis—did not ap-
pear the most represented profile in the aMCI group.
Follow-up is needed to confirm the evolution of these
patients, according to their baseline biomarker profile.
Recently, Jack et al. estimated in a large cohort of sub-
jects the prevalence of three biomarker-based definitions
of the AD-continuum from the NIA-AA-RF and com-
pared it with the prevalence of three clinically defined
diagnostic entities commonly associated with AD (MCI,
dementia, and clinically defined probable AD). They
found that biologically defined AD is more prevalent
than clinically defined probable AD, possibly due to the
asymptomatic individuals with biological AD [38]. Au-
thors concluded that the two definitions create potential
confusion around the term AD [38].
The last consideration regards the correspondence be-
tween CSF and PET Aβ biomarkers. As previously de-
scribed [4, 19, 25, 31, 32, 39, 40], we confirmed a slight
inverse correlation between CSF Aβ1-42 levels, and the
binding of amyloid-PET tracer in total GM and precu-
neus. As speculated by Palmiqvist et al., this could indi-
cate that CSF Aβ1-42 reflects the total aggregation status
of Aβ1-42 in the whole brain [39]. When we applied the
CSF Aβ1-42 cut-off based on amyloid-PET positivity,
concordance was present in 89% of the subjects. Many
different studies had previously investigated the agree-
ment between PET and CSF data, reporting rates ran-
ging from 72 to 92.4% [4, 5, 18, 25, 30, 33, 41]. The
variable concordance between the two biomarkers has
different explanations. Illàn-Gala et al. recently described
a variable correlation between CSF Aβ1-42 levels and
amyloid-PET data that was good in CU and MCI, but
negligible in dementia [42]. Toledo and colleagues dem-
onstrated a non-linear correlation between CSF and PET
Aβ biomarkers [42, 43]. Recent studies have demon-
strated that aP−/CSF+ subjects have increased rates of
Aβ accumulation, and are likely to become aP+ [39, 44],
suggesting that the two biomarkers measure AD path-
ology at different stages [4, 42]. CSF reflects soluble
forms of Aβ that precede fibrillary deposition, and pos-
sibly becomes abnormal prior to PET [4, 39, 45]. In line
with this observation, our two aP−/CSF+ patients had a
diagnosis of aMCI and developed a clinically defined AD
at follow-up. aP+/CSF− individuals have also been re-
ported among both CU and CI [5, 7, 25, 46]. However,
these subjects have usually elevated CSF t-tau and p-tau
levels, and Aβ1-42 close to the cut-off, and are often diag-
nosed with MCI or AD. Different methodologies may
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also highly influence the proportions of CSF+ and/or
aP+ subjects. Among the three aP+/CSF− participants
we had in our study, two had elevated CSF t-tau and p-
tau levels and one had nearly pathologic CFS Aβ1-42
levels (665 pg/ml). All of them had a clinical diagnosis of
AD or mixed/VaD dementia. Lastly, the application of
the 2018-NIA-AA-RF to those patients who performed
both PET and CSF analysis confirmed a larger discord-
ance in aP− participants, suggesting that the chosen CSF
and neuroimaging markers of Aβ deposition are not per-
fectly interchangeable.
This work has several limitations. First, a gold stand-
ard for the assessment of cortical Aβ burden is lacking.
In line with previous literature, we chose amyloid-PET
as the best surrogate in vivo marker for determining the
Aβ load because of its easy interpretation by visual in-
spection and its high correlation with neuropathological
studies [5, 18, 20–23]. Even though ROC analyses and
group comparisons are statistically significant, we are
aware that there were relatively few aP− subjects, in
comparison to aP+. The subgroup of participants with
both CSF and PET data was small, and the average time
interval between LP and amyloid-PET was of approxi-
mately 6 months. All these aspects might have influ-
enced our findings. Moreover, the CSF positivity
thresholds were defined based on maximising the dis-
crimination between aP+ and aP− subjects, without an
independent test set. Thus, the correspondence we de-
scribed between CSF and PET data likely represents an
upper limit. It should also be noted that the incorpor-
ation of biomarkers into some AD diagnosis may have
biased the concordance between biomarker- and clinic-
ally based diagnoses. Due to lack of data, patients were
classified considering CSF data only and Aβ deposition
was measured without considering Aβ42/40 ratio, which
is recently considered as having an improved diagnostic
performance compared to Aβ42 alone [19]. Illàn-Gala
et al. evaluated the consistency of the AT(N) classifica-
tion with different biomarker combinations, finding im-
portant divergences and concluding that it does not
achieve the required consistency to be used in clinical
settings [42].
Conclusions
The application of the new criteria to a large cohort of
patients revealed a good, but incomplete, correspond-
ence between the clinical syndromes and the underlying
pathologic process as measured by CSF biomarkers.
The AD-continuum profile resulted to be a sensitive,
but non-specific biomarker with regard to the clinical
AD diagnosis. The incomplete agreement we found
between CSF and PET Aβ biomarkers suggests that
they are not perfectly interchangeable to quantify the
Aβ burden, possibly because they measure different
features of AD pathology.
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